Fig 1: In vivo effects of a-IL-10R application on lupus pathology and immune status in NZB/W F1 animals. 20–22 week old NZB/W F1 animals with detectable a-dsDNA antibodies were treated with a-IL-10R or isotype control (n (a-IL-10R) = 11–13 mice; n (isotype) = 13 mice) at a dose of 500 µg every 3 weeks over 6 weeks. Clinical disease progression and impact on immunologic changes were determined by: (a) development of proteinuria depicted as trend line with mean ± SEM for each time point; (b) levels of a-dsDNA IgG1, IgG2a, IgG2b and IgG3 before and after treatment; indicated are the percentages of animals with an a-dsDNA titer increase >10×, of 1,5–10× and <1,5× as pie graph; (c) kidney infiltration by CD45+ leukocytes; (d) lymphoproliferation by splenomegaly; and (e) immune status evaluation using flow cytometry in spleen 1 week after termination of a-IL-10R or isotype treatment; depicted are relative changes in neutrophils, monocytic cells and CD4 and CD8 T cells, in CXCR5hiPD1hi TFH, FashiGL7hi GC B cells, CD138hi plasma cells and their expression of IgG1, IgG2a, IgG2b and IgG3. (a,c–e) The p value was calculated using a Mann–Whitney test to determine the difference between isotype- and a-IL-10R-treated animals. Results are expressed as scatter blots with mean ± SEM; each data point represents an individual mouse.